Smith & Nephew plc (NYSE:SNN) Receives $27.50 Consensus Target Price from Analysts

Shares of Smith & Nephew plc (NYSE:SNN) have been assigned a consensus recommendation of “Hold” from the nine analysts that are currently covering the firm, MarketBeat Ratings reports. Five analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $27.50.

A number of equities research analysts have recently issued reports on SNN shares. Berenberg Bank raised shares of Smith & Nephew from a “hold” rating to a “buy” rating in a report on Tuesday, July 23rd. Canaccord Genuity reissued a “buy” rating and set a $6.00 price target on shares of Smith & Nephew in a research report on Friday, May 3rd. Finally, Zacks Investment Research raised shares of Smith & Nephew from a “hold” rating to a “buy” rating and set a $49.00 price target on the stock in a research report on Tuesday, July 2nd.

Several hedge funds have recently made changes to their positions in the company. Squarepoint Ops LLC acquired a new position in Smith & Nephew in the fourth quarter valued at about $206,000. Laurion Capital Management LP acquired a new position in Smith & Nephew in the first quarter valued at about $1,774,000. NumerixS Investment Technologies Inc lifted its position in Smith & Nephew by 38.9% in the first quarter. NumerixS Investment Technologies Inc now owns 5,000 shares of the medical equipment provider’s stock valued at $200,000 after buying an additional 1,400 shares during the last quarter. Dalton Greiner Hartman Maher & Co. lifted its position in Smith & Nephew by 211.5% in the first quarter. Dalton Greiner Hartman Maher & Co. now owns 267,817 shares of the medical equipment provider’s stock valued at $10,742,000 after buying an additional 181,851 shares during the last quarter. Finally, Checchi Capital Advisers LLC acquired a new position in Smith & Nephew in the first quarter valued at about $201,000. 8.74% of the stock is currently owned by hedge funds and other institutional investors.

Smith & Nephew stock opened at $44.68 on Friday. Smith & Nephew has a 52-week low of $32.22 and a 52-week high of $47.05. The stock has a market capitalization of $19.94 billion, a price-to-earnings ratio of 22.12, a price-to-earnings-growth ratio of 3.20 and a beta of 0.28. The business’s fifty day simple moving average is $43.94. The company has a debt-to-equity ratio of 0.40, a current ratio of 2.00 and a quick ratio of 0.96.

Smith & Nephew Company Profile

Smith & Nephew plc develops, manufactures, and sells medical devices worldwide. The company offers sports medicine joint repair products for surgeons, including an array of instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder.

See Also: Intrinsic Value

Analyst Recommendations for Smith & Nephew (NYSE:SNN)

Receive News & Ratings for Smith & Nephew Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew and related companies with MarketBeat.com's FREE daily email newsletter.